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Background: Goal of this retrospective analysis was to evaluate the role of repeat whole brain radiotherapy in the
palliative care of patients with brain metastases due to solid tumors.
Methods: Data regarding demographic data, primary tumor, metastasis, radiotherapy and symptoms were
compiled on 134 patients with cerebral metastases that received repeat whole brain radiotherapy (WBRT) in our
clinic between 2002 and 2011.
Results: The analyzed group consisted of 63 (47%) women and 71 (53%) men with a median age of 57 at the start
of re-irradiation. Most frequent primary site was the lung (87%).
Sixty patients with lung cancer received the first WBRT prophylactically. At the time of re-WBRT 81% of all patients
suffered from additional extracerebral metastases.
Time between first and second WBRT was a median of 13.4 months. Full dose for the first WBRT was 30 Gy in
2.0 Gy single dose, for the second 20 Gy in 2.0 Gy single dose.
At the start of the Re-WBRT 81 patients (60.4%) had mild, 32 (23.9%) severe neurological symptoms, 21 patients
(15.7%) were asymptomatic. The median Karnofsky performance status was 70%. Overall, re-WBRT was tolerated
satisfactorily. Main side effects were fatigue, erythema and focal alopecia, 10% of patients discontinued treatment
before reaching the planned dose. Median survival was 2.8 months since the end of the re-WBRT with good performance
status at the start of the re-irradiation being a key indicator for longer survival.
Fifty-two patients (39%) showed a clinical improvement of neurological symptoms after the therapy, 59 patients (44%)
remained stable, 23 patients (17%) showed worse symptoms.
Conclusions: From this large patient collective we were able to show that re-WBRT can be an important therapeutic
option with low rate of acute side effects for patients in adequate general condition.
Keywords: Re-irradiation, Brain metastasis, Cerebral metastasis, Whole brain radiotherapy, Palliative care, Solid
tumors, Effectiveness, SafetyBackground
Cerebral metastases pose a significant health care prob-
lem. 20-40% of cancer patients develop brain metastases
during the course of their disease [1] and numbers are
likely to increase due to improved systemic treatment
and resulting increase in survival times. Prognosis for
these patients is generally poor with a median survival of
4–5 months [2], however, patients often present in* Correspondence: henrik.hauswald@med.uni-heidelberg.de
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stated.overall acceptable performance status, with a strong
wish for additional treatment. While treatment options
include surgery, chemotherapy and irradiation, whole
brain radiotherapy (WBRT) is considered standard of
care especially for patients with multiple metastases
[3,4]. Unfortunately, in general, the effect is not very
enduring, and time to clinical progression after WBRT
lies between 6 and 13 weeks [5].
Treatment options in this recurrent situation, espe-
cially for patients with multiple lesions, are limited, in-
cluding re-irradiation, surgery, best supportive care and,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Table 1 Patient characteristics
n %
Sex
Male 71 53%
Female 63 47%
Age
18-49 years 27 20%
50-59 years 51 38%
≥60 years 56 42%
Primary Site
Lung thereof SCLC 117 81 87% 60%
Breast 12 9%
Other 5 4%
Year of re-irradiation
2009 or before 55 41%
2010 41 31%
2011 38 28%
RPA class
RPA 1 6 5%
RPA 2 83 62%
RPA 3 45 34%
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decided individually based on the patient’s general per-
formance status, extracranial disease, number of metas-
tases, primary malignancy and previous treatments [6].
While patients with a small number of metastases might
be treated by stereotactic radiosurgery [7,8], options are
extremely limited in the case of multiple metastases.
Re-WBRT can be an important treatment option, espe-
cially for patients with stable extracranial disease and
sufficient general performance status. However, most
institutions are hesitant to apply a second course of
WBRT due to a fear of toxicity, thus reports on Re-
WBRT and treated patient numbers are relatively low.
Comparative analyses are missing and patient numbers
in the existing studies are not sufficient to lead to
general recommendations [9].
In our institution, the indication for Re-WBRT is seen
depending on overall performance status of the patients,
underlying disease, and other comorbidities. In the present
analysis we evaluated our group of patients with recurrent
or progressive brain metastases treated with Re-WBRT
with the objective to examine survival following re-
irradiation. The group represents one of the larger
groups of patients published to date treated in a single
center with a homogenous treatment algorithm.
Methods
We identified 134 patients in our cancer center database
that had received Re-WBRT in our department between
2002 and 2011. Patients treated for malignant myeloma,
metastases of the skull or primary brain tumors were
excluded. We also excluded all treatments that were not
whole brain radiotherapy, e.g., stereotactic radiosurgery,
partial-brain radiotherapy etc. The study was approved
by the ethics committee Heidelberg.
From the patient charts we retrieved the following
data: age, primary malignancy including stage and grad-
ing, extracranial disease status, first diagnosis and num-
ber of brain metastases, dose and fractionation of first
and second WBRT, symptoms before and after irradi-
ation, response to re-irradiation, additional treatment,
side effects of irradiation, progression of metastases,
treatment as in- or outpatient.
Symptoms were classified as asymptomatic, mild symp-
toms and severe symptoms based on description in the
patient charts. Signs of intracerebral pressure, hemiparesis
or general seizures where classified as severe symptoms,
neurocognitive testing was not performed on a regular
basis.
Karnofky performance status (KPS) was taken from
patient records for 50% of patients. If no KPS was indi-
cated in the records, the value was estimated based on
the description of the patient’s clinical status at the rele-
vant time point.All patients were assigned an RPA (recursive partition-
ing analysis) class based on KPS, local control, extracranial
metastases status and age. Patients ≤ 65, with a KPS ≥ 70,
local control and no extracranial metastases were assigned
RPA class I. Patients with a KPS < 70 were assigned RPA
class III, all others were assigned to group II.
Progression after therapy was based on clinical evalua-
tions or imaging where possible. Patients were invited to
regular follow-up visits till their death with a median
follow-up of 2.1 months.
Date of death was obtained from medical and official
records.
Statistical analyses were conducted with SPSS version
16.0.1 (SPSS Inc., Chicago, IL, USA) using Cox regres-
sion analyses (stepwise backwards, p-in 0.05, p-out 0.1),
log-rank test and Kaplan-Meier method. If not declared
otherwise, survival time was defined as the time period
between the last day of re-irradiation and date of death.
Statistical significance was defined as p < 0.05.
Results
134 patients received a second course of whole brain
radiotherapy in our institution between 2002 and 2011
with the number of re-irradiations/year increasing sig-
nificantly over the years. Patient characteristics are listed
in Table 1. 63 patients (47%) were female and 71 (53%)
were male. The median age at the start of the Re-WBRT
was 57 (range 31–82). The main primary tumor site was
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9%) and others (two malignant melanoma, two carcin-
oma of unknown primary and one lung cancer with
synchronous malignant melanoma).
At the time of the Re-WBRT the primary tumor was
locally controlled in 36 cases (27%) and not controlled
in 95 cases (71%), for 3 patients no relevant data was
available. 43 patients (32%) had additional metastases in
one extracerebral location, 66 patients (49%) had metas-
tases in at least two extracerebral locations prior to
re-irradiation, only 25 patients (19%) had no additional
metastases.
The median dose for the first WBRT was 30 Gy in
2.0 Gy fractionation (range 30–40 Gy). The median time
interval between the first and the second WBRT was
13.4 months (range 3.4-58.8 months).
Sixty patients with lung cancer received the first whole
brain irradiation prophylactically, the other 74 had radio-
logically confirmed cerebral metastases, the median time
interval between the first and the second WBRT were
almost the same for the two groups (13.5 and 13.4 months).
The median dose for the second WBRT was 20 Gy in
2.0 Gy fractions (range 2–30 Gy).
The mean Karnofsky performance status (KPS) at the
time of retreatment was 70% (range 40-100%) both for
only the group that had a KPS indicated in records and
for the whole cohort. The majority of patients (81
patients, 61%) had mild neurological symptoms, 32
patients (24%) had severe symptoms, 21 patients (16%)
were asymptomatic.Figure 1 Overall survival after re-irradiation (Kaplan-Meier’s estimatioBased on KPS, age, local control and extracranial
metastasis at the time of retreatment, the majority of
patients (83 patients, 61.9%) was classified as RPA class
II, 6 patients (4.5%) were classified as RPA class I, 45
patients (33.6%) were classified as RPA class III. Median
survival was 2.8 months (0–28 months) since start of re-
irradiation (Figure 1), 10.2 months since the initial diag-
nosis of brain metastases and 23.9 months since primary
diagnosis.
At the end of the therapy 52 patients (39%) showed
clinical improvement of neurological symptoms, 59 pa-
tients (44%) had no relevant change, 23 patients (17%)
showed more severe symptoms.
Patients with small cell lung cancer (SCLC) had the
shortest overall survival (median 2.3 months) with the
other primary sites ranging between 3.9 and 4.3 months
with SCLC being a significant negative predictive factor in
univariate analysis (Figure 2). Patients that had received
the first whole brain irradiation prophylactically showed a
significantly lower overall survival than those that had
received the first WBRT therapeutically (p = 0.002). How-
ever, analyzing only the SCLC subgroup there was no
significant difference in overall survival between those pa-
tients that received their first irradiation prophylactically
and those that received it therapeutically.
Higher overall survival was found for patients whose
primary tumors were controlled at the time of re-
irradiation with median survival of 3.8 months while
those without extracerebral control had a median of
2.4 months survival (p = 0.01). Another predictive factorn).
Figure 2 Overall survival depending on primary tumor site (Kaplan-Meier’s estimation). SCLC with significantly worse prognosis (p = 0.002, log-rank-test).
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tients with a Karnofsky performance status of ≥80 had a
median survival of 4.9 months, compared to 3.1 months
for those with a performance status of 70 and 2.1 months
for those with a performance status of <70 (p < 0.001).
These were both reflected in the RPA class with RPA class
3 being a negative predictive factor (Figure 3). Small cell
lung cancer, primary tumor progression and low Kar-
nofsky performance status were also identified as negative
predictive factors in the multivariable Cox-regression ana-
lysis (Table 2) with more severe symptoms showingFigure 3 Overall survival depending on RPA class (Kaplan-Meier’s estimatborderline significance. Male sex was a negative predictive
factor in univariate, but not in multivariable analysis.
Age, time between course 1 and 2 of the irradiation
and dose of irradiation did not have any predictive value.
Only 28 patients (20.9%) could conduct the whole ther-
apy as out-patients. 11 (8.2%) were at least partially treated
as inpatients and 95 (70.9%) were completely treated as
inpatients. Among these 95 patients, 45.3% were classified
as RPA 3 and showed a Karnofsky-Index <70, compared
to 3.6% in the group that conducted the whole therapy as
out-patients.ion). RPA class 3 with significantly worse prognosis (p = 0.002, log-rank-test).
Table 2 Multivariable analysis
Factor analyzed Negative
predictive
factor
p-value Hazard ratio
(95% CI)
Primary tumor SCLC 0.019 0.59 (0.38 – 0.92)
Extracerebral control No control of
primary
<0.001 2.32 (1.47 – 3.66)
Karnofsky performance
status
KPS <70 0.038 n/a**
Higher RPA class RPA 3 n/a* n/a**
Symptoms Severe
symptoms
0.070 n/a**
Interval between
WBRT 1 and 2
0.557 1.12 (0.76 – 1.65)
Dose for re-irradiation 0.586 1.18 (0.65 – 2.16)
Male gender 0.087 1.45 (0.95 – 2.22)
Age≥ 60 0.773 1.07 (0.69 – 1.65)
*Linearly dependent on Karnofsky performance status.
**Co-linearity between KPS, RPA and symptoms, therefore no individual
hazard ratios.
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torily. Main side effects were focal alopecia, fatigue, ver-
tigo and erythema, few patients also showed more severe
neurological symptoms like mnestic deficits, speech im-
pairment or ataxia (Table 3). 14 patients (10.5%) had to
discontinue treatment early with a slightly higher rate
(12.6%) among those that were treated fully as in-patients.
Discussion
While several retrospective studies have analyzed the
effects of re-irradiation in patients with brain metastases
from solid tumors, the numbers of analyzed patients are
low with no study consisting of more than 100 patients
[9-16]. The largest collectives to date were analyzed by
Wong et al. with 86 patients [14] and Sadikov et al. with
72 patients [16].Table 3 Rate of adverse symptoms after irradiation
Symptom n %
No adverse symptoms 44 33%
(Focal) Alopecia 29 22%
Fatigue 18 13%
Vertigo 16 12%
Erythema 15 11%
General weakness 14 10%
Mnestic deficits 13 10%
Difficulty swallowing, oral thrush 10 8%
Headache 10 8%
Nausea/vomiting 9 7%
Speech or sensory impairment 7 5%
Ataxia 3 2%Over the years, radiation oncologists have become
more generous when indicating a second course of
WBRT, especially in patients where time to prior WBRT
is longer and extracranial disease remains controlled.
This trend is reflected also in our data, where a strong
increase in patients/year treated with WBRT can be seen
during the observation period.
Wong et al. and Sadikov et al. as well as most of the
other studies come to the conclusion that repeat whole
brain radiotherapy is efficient and safe enough to be
accepted as a treatment that provides symptomatic relief
to patients with a very limited prognosis. Our patient
collective supports these results in showing that repeat
whole brain radiotherapy can be an important thera-
peutic option with low rate of acute side effects for pa-
tients in adequate general condition. We have added our
results to a summary first published by Sadikov et al.
[16] and updated by Son et al. [9] to show an overview
of previously published studies regarding re-irradiation
of brain metastases (Table 4).
For the initial radiotherapy our median of 30 Gy in 15
fractions is in accordance with the doses and number of
fractions used in most other studies. Shehata et al. [10],
Kurup et al. [11] and Sadikov et al. [16] used a lower
dose with a lower number of fractions with no obvious
difference in outcome or toxicity. For the Re-WBRT in
the majority of cases we applied 20 Gy in 10 fractions, a
dose and number of fractions on the lower end of the
spectrum of analyzed studies. Only Shehata et al. used a
one-time irradiation of 10 Gy, while in all other cases 8–
12 fractions were used. Abdel-Wahab et al. [15] analyzed
the only patient collective where the Re-WBRT was ap-
plied as a partial brain therapy twice daily thereby dupli-
cating the number of fractions.
With 13.4 months between first and second whole
brain radiotherapy our interval was longer than that of
most previous studies except for Son et al. with 15
months [9]. A reason for that could be the high number
of patients with small cell lung cancer in our analysis
that received the first whole brain radiotherapy prophy-
lactically before they had developed brain metastases.
Additionally, our internal guidelines recommend Re-
WBRT only after a minimum of 6 months after primary
WBRT, therefore rapidly progressive patients are not
treated with Re-WBRT.
Response rates vary strongly between the different
analyses. Hazuka and Kinzie [12] showed the lowest rate
of improved symptoms with 27% while Son et. al. found
improved symptoms in 80% of cases. These variances
are probably due to the subjectivity of symptoms, espe-
cially if determined retrospectively based on patient
charts and doctor’s notes. Our patients showed an im-
provement of symptoms in 39% of cases, stable symp-
toms in 44% and worsening symptoms in 17%, all
Table 4 Re-irradiation for cerebral metastases: overview of publications
Shehata
et al. [10]
Kurup et al. [11] Hazuka and
Kinzie [12]
Cooper
et al. [13]
Wong et al. [14] Abdel-Wahab
et al. [15]
Sadikov et al. [16] Son et al. [9] Present study
n 35 56 44 52 86 15 72 17 134
Initial RT 1×10 Gy, 3×6 Gy 10×3 Gy 10×3 Gy 10×3 Gy 15×2 Gy 5×4 Gy 14×2.5 Gy 15×2 Gy
10×3 Gy
Re-RT 1×10 Gy 10×2 Gy 8×3.125 Gy 10×2.5 Gy 10×2 Gy 20×1.5 Gy twice daily
(partial brain)
10×2.5 Gy 12×1.8 Gy 10×2 Gy
Interval - 6.3 mo (mean) 7.8 mo (median) > 4 mo 7.6 mo (median) 10 mo (median) 9.6 mo (median) 15 mo (median) 13.4 mo (median)
Response
Improve 68% 75% 27% 42% 70% 60% 40% 80% 39%
Stable 25% 12.5% 41% 52% 29% 27% 33% 20% stable or no response 44%
None 12.5% 14% 6% 33% 17%
Toxicity 17% acute side
effects
18% acute side effects
1 radiation necrosis
8 autopsies, 3
brain necroses
- 5 patients with
radiographic
abnormality
1 patient with severe
side effects 3 unable
to complete RT
71% with acute side effects 67% with acute side
effects 10% unable
to complete RT
Survival after
re-irradiation
- 3.5 mo median 2 mo median 4 mo median 4 mo median 3.2 mo median 4.1 mo median 5.2 mo median 2.8 mo median
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found in other studies. A confounding factor in our as
well as all other studies could have been the use of ste-
roids that often improve the most severe symptoms be-
fore the radiotherapy has even started. However, due to
the retrospective nature of the present analysis, detailed
information on steroids, neuro-cognitive performance,
quality of life and also imaging-defined progression-free
survival are difficult to assess; also, KPS was only directly
available for 50% of patients with the other being esti-
mated due to performance as described in patient
records; moreover, these endpoints are considered soft
endpoints dependent on many clinical as well as per-
sonal factors, therefore, the focus of the present work
was set on the hard endpoint survival.
While 10% of patients had to discontinue treatment
before the planned dose was reached, treatment was
generally tolerated well with minor side effects including
as most common symptoms alopecia, fatigue, vertigo
and erythema. Few patients showed more severe neuro-
logical symptoms like mnestic deficits, speech impair-
ment and ataxia. The relatively low incidence of side
effects might be due to the fact that a majority of
patients received the first WBRT prophylactically with a
common scheme of 15×2 Gy resulting in a lower equiva-
lent dose than patients treated therapeutically with often
10×3 Gy. One limitation in assessing side effects is, that
it is difficult to differentiate whether these symptoms
were caused by the progressive metastases or the whole
brain radiotherapy. Due to the progressive state of their
disease and the resulting low performance status most
patients had to be treated as in-patients.
Median survival after Re-WBRT was 2.8 months, the
second lowest in all of the before mentioned studies.
Median survival in the other studies was between 2 and
5.2 months. Only Kurup et al., Wong et al. and Son
et al. also determined time to progression which was be-
tween 2.5 and 2.75 months. One reason why our survival
is lower than that of most other studies could be the
relatively high number of patients with SCLC that show
a significantly worse outcome than patients with other
primary tumors. This is likely also the reason why patients
that had received the first whole brain irradiation prophy-
lactically showed a significantly lower overall survival. A
subgroup analysis of the patients with SLCS could not
confirm the difference in overall survival between those
patients that received their first irradiation prophylactic-
ally and those that received it therapeutically.
To evaluate the effects of different variables on overall
survival, a stepwise backwards multivariable analysis
was conducted. While the stepwise approach has cer-
tain limitations (Harrell in [17]), it still provides an im-
portant additional view, e.g., highlighting the fact that
lower survival of male patients is likely due not to theirsex, but to the higher prevalence of SCLC among this
group.
As the RPA group is directly dependent on the KPI,
no p-value could be obtained for this variable in the
stepwise backwards analysis.
Conclusions
While depending on histology and number of metastases
WBRT is a standard of care in patients with newly diag-
nosed brain metastases as stated by the newest guide-
lines of the American Society for Radiation Oncology
[18], treatment in the recurrent situation poses a thera-
peutic challenge. In the past, in general, no second
course of WBRT was performed, due to the fear of
treatment-related side effects. With our patient collect-
ive we could show that repeat whole brain radiotherapy
can be an important therapeutic option with low rate of
acute side effects for patients in adequate general
condition.
Treatment should be weighed against supportive ther-
apy with steroids alone, especially for patients with a low
performance status that often have to be treated as
inpatients.
For patients with a sufficient performance status, pro-
spective, randomized studies with higher patient number
will be needed to allow the better identification of pa-
tients that could benefit most from re-irradiation and to
determine the ideal dose and fractionation. Therefore,
the randomized ERASER-Trial comparing best support-
ive care, low-dose Re-WBRT with 20 Gy as well as Re-
WBRT with 30 Gy is currently being prepared and will
start recruitment soon.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
HH participated in the design of the study and helped to conduct the
statistical analyses. MS performed all analyses and drafted the manuscript.
MB and JD participated in the design of the study and reviewed the results.
SC conceived of the study, participated in its design and helped to draft the
manuscript. All authors read and approved the final manuscript.
Received: 7 September 2013 Accepted: 26 December 2013
Published: 3 January 2014
References
1. Soffietti R, Rudà R, Trevisan E: Brain metastases: current management and
new developments. Curr Opin Oncol 2008, 20:676–684.
2. Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE,
Schmitz PI: Identification of prognostic factors in patients with brain
metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 1999,
43:795–803.
3. Gaspar LE, Mehta MP, Patchell RA, Burri SH, Robinson PD, Morris RE,
Ammirati M, Andrews DW, Asher AL, Cobbs CS, Kondziolka D, Linskey ME,
Loeffler JS, McDermott M, Mikkelsen T, Olson JJ, Paleologos NA, Ryken TC,
Kalkanis SN: The role of whole brain radiation therapy in the
management of newly diagnosed brain metastases: a systematic review
and evidence-based clinical practice guideline. J Neurooncol 2010,
96:17–32.
Scharp et al. Radiation Oncology 2014, 9:4 Page 8 of 8
http://www.ro-journal.com/content/9/1/44. Hauswald H, Dittmar J-O, Habermehl D, Rieken S, Sterzing F, Debus J,
Combs SE: Efficacy and toxicity of whole brain radiotherapy in patients
with multiple cerebral metastases from malignant melanoma. Radiat
Oncol 2012, 7:130.
5. Borgelt B, Gelber R, Kramer S, Brady LW, Chang CH, Davis LW, Perez CA,
Hendrickson FR: The palliation of brain metastases: final results of the
first two studies by the Radiation Therapy Oncology Group. Int J Radiat
Oncol Biol Phys 1980, 6:1–9.
6. Ammirati M, Cobbs CS, Linskey ME, Paleologos NA, Ryken TC, Burri SH,
Asher AL, Loeffler JS, Robinson PD, Andrews DW, Gaspar LE, Kondziolka D,
McDermott M, Mehta MP, Mikkelsen T, Olson JJ, Patchell RA, Kalkanis SN:
The role of retreatment in the management of recurrent/progressive
brain metastases: a systematic review and evidence-based clinical
practice guideline. J Neurooncol 2010, 96:85–96.
7. Akyurek S, Chang EL, Mahajan A, Hassenbusch SJ, Allen PK, Mathews LA,
Shiu AS, Maor MH, Woo SY: Stereotactic radiosurgical treatment of
cerebral metastases arising from breast cancer. Am J Clin Oncol 2007,
30:310–314.
8. Combs SE, Schulz-Ertner D, Thilmann C, Edler L, Debus J: Treatment of
cerebral metastases from breast cancer with stereotactic radiosurgery.
Strahlenther Onkol 2004, 180:590–596.
9. Son CH, Jimenez R, Niemierko A, Loeffler JS, Oh KS, Shih HA: Outcomes
after whole brain reirradiation in patients with brain metastases.
Int J Radiat Oncol Biol Phys 2012, 82:e167–172.
10. Shehata WM, Hendrickson FR, Hindo WA: Rapid fractionation technique
and re-treatment of cerebral metastases by irradiation. Cancer 1974,
34:257–261.
11. Kurup P, Reddy S, Hendrickson FR: Results of re-irradiation for cerebral
metastases. Cancer 1980, 46:2587–2589.
12. Hazuka MB, Kinzie JJ: Brain metastases: results and effects of re-irradiation.
Int J Radiat Oncol Biol Phys 1988, 15:433–437.
13. Cooper JS, Steinfeld AD, Lerch IA: Cerebral metastases: value of
reirradiation in selected patients. Radiology 1990, 174:883–885.
14. Wong WW, Schild SE, Sawyer TE, Shaw EG: Analysis of outcome in patients
reirradiated for brain metastases. Int J Radiat Oncol Biol Phys 1996,
34:585–590.
15. Abdel-Wahab MM, Wolfson AH, Raub W, Landy H, Feun L, Sridhar K,
Brandon AH, Mahmood S, Markoe AM: The role of hyperfractionated
re-irradiation in metastatic brain disease: a single institutional trial.
Am J Clin Oncol 1997, 20:158–160.
16. Sadikov E, Bezjak A, Yi Q-L, Wells W, Dawson L, Millar B-A, Laperriere N:
Value of whole brain re-irradiation for brain metastases–single centre
experience. Clin Oncol (R Coll Radiol) 2007, 19:532–538.
17. Harrell, Frank E: Regression Modeling Strategies. Springer; 2002. ISBN
978-1-4757-3462-1.
18. Tsao MN, Rades D, Wirth A, Lo SS, Danielson BL, Gaspar LE, Sperduto PW,
Vogelbaum MA, Radawski JD, Wang JZ, Gillin MT, Mohideen N, Hahn CA,
Chang EL: Radiotherapeutic and surgical management for newly
diagnosed brain metastasis(es): An American Society for Radiation
Oncology evidence-based guideline. Pract Radiat Oncol 2012, 2:210–225.
doi:10.1186/1748-717X-9-4
Cite this article as: Scharp et al.: Re-irradiation in the treatment of
patients with cerebral metastases of solid tumors: retrospective analysis.
Radiation Oncology 2014 9:4.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
